Baylor Health Care SystemAbout B
Research: From moving better to recovering faster, here's what we're studying. 
Need something? Call us: 1.800.4BAYLOR(1.800.422.9567)
Text Size:


A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer (11167)

Study Description:

The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.

Inclusion Criteria:

» Subjects must be at least 18 years of age
» Subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to enrollment
» Subjects must understand and sign an informed consent form

Exclusion Criteria:


Texas Oncology - Baylor Charles A. Sammons Cancer Center
3410 Worth Street
Dallas , TX 75246

Texas Oncology - Baylor All Saints Medical Center at Fort Worth
1400 Eighth Avenue
Fort Worth , TX 76104

Lead Principal Investigator:

Asad Dean, MD (Fort Worth); Charles Cowey, MD (Dallas)

For further information regarding this study, please contact the Office of Clinical Oncology Research Coordination at 214-818-8472 or via email at

Last update: December 31, 2012
† Baylor Research Institute and Texas Oncology are not affiliated. Each reviews, approves, and conducts clinical trials independently. Their clinical trials are listed together on this website for the convenience of patients.